Abstract
AbstractThe RE1-silencing transcription factor (REST) acts either as a repressor or activator of transcription depending on the genomic and cellular context. REST is a key player in brain cell differentiation by inducing chromatin modifications, including DNA methylation, in a proximity of its binding sites. Its dysfunction may contribute to oncogenesis. Mutations in IDH1/2 significantly change the epigenome contributing to blockade of cell differentiation and glioma development. We aimed at defining how REST modulates gene activation and repression in the context of the IDH mutation-related phenotype in gliomas. We studied the effects of REST knockdown, genome wide occurrence of REST binding sites, and DNA methylation of REST motifs in IDH wild type and IDH mutant gliomas. We found that REST target genes, REST binding patterns, and TF motif occurrence proximal to REST binding sites differed in IDH wild-type and mutant gliomas. Among differentially expressed REST targets were genes involved in glial cell differentiation and extracellular matrix organization, some of which were differentially methylated at promoters or gene bodies. REST knockdown differently impacted invasion of the parental or IDH1 mutant glioma cells. The canonical REST-repressed gene targets showed significant correlation with the GBM NPC-like cellular state. Interestingly, results of REST or KAISO silencing suggested the interplay between these TFs in regulation of REST-activated and repressed targets. The identified gene regulatory networks and putative REST cooperativity with other TFs, such as KAISO, show distinct REST target regulatory networks in IDH-WT and IDH-MUT gliomas, without concomitant DNA methylation changes. We conclude that REST could be an important therapeutic target in gliomas.
Funder
Narodowe Centrum Nauki
Fundacja na rzecz Nauki Polskiej
Publisher
Springer Science and Business Media LLC
Reference78 articles.
1. Ballas N, Grunseich C, Lu DD, Speh JC, Mandel G (2005) REST and its corepressors mediate plasticity of neuronal gene chromatin throughout neurogenesis. Cell 121:645–657
2. Arizmendi-Izazaga A, Martínez-Baltazar R, Liborio-Bautista A, Olea-Flores M, Ortiz-Ortiz J, Navarro-Tito N (2023) The NRSF/REST transcription factor in hallmarks of cancer: from molecular mechanisms to clinical relevance. Biochimie 206:116–134
3. Jm C, Jl E, Pj W, Jp Q. A splice variant of the neuron-restrictive silencer factor repressor is expressed in small cell lung cancer: a potential role in derepression of neuroendocrine genes and a useful clinical marker. Cancer research [Internet]. 2000 [cited 2024 Mar 27];60. Available from: https://pubmed.ncbi.nlm.nih.gov/10766169/
4. Westbrook TF, Martin ES, Schlabach MR, Leng Y, Liang AC, Feng B et al (2005) A genetic screen for candidate tumor suppressors identifies REST. Cell 121:837–848
5. Reddy BY, Greco SJ, Patel PS, Trzaska KA, Rameshwar P (2009) RE-1–silencing transcription factor shows tumor-suppressor functions and negatively regulates the oncogenic TAC1 in breast cancer cells. Proc Natl Acad Sci 106:4408–4413